Rhythm Biosciences (ASX:RHY) secures a reinstatement of its National Association of Testing Authorities accreditation for the geneType cancer risk assessment assay portfolio, according to a Tuesday filing with the Australian bourse.
This follows the temporary suspension of the accreditation after the company acquired the geneType assets from Genetic Technologies (ASX:GTG), the filing said.
The reinstatement marks the conclusion of the integration of the geneType laboratory under the company's ownership, per the filing.
Shares were down 3% in afternoon trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.